

DETAILED PROGRAM

33rd ANNUAL MEETING OF THE EUROPEAN
SOCIETY FOR HYPERTHERMIC ONCOLOGY

Wednesday 22nd May 2019

08:45-09:45 **Meta-analysis of clinical trials with hyperthermia**
N.R. Datta

09:45-10:45 **Hyperthermia heating devices**
J. Crezee

10:45-11:15 **COFFEE**

11:15-12:15 **Opportunities of HIFU for thermal therapy**
H. Gröll

12:15-13:15 **LUNCH**

13:15-14:15 **Magnetic fluid hyperthermia: Advances and challenges
for its translation to the clinic**
T. Samaras

14:15-15:15 **Modelling HT-RT: BED and transient biological dose
equivalent TBDE**
S. Scheidegger

15:15-15:45 **COFFEE**

15:45-16:45 **Molecular effects of hyperthermia**
R. Kanaar



17:00-17:35 **OPENING CEREMONY**

Speech of congress president

dr hab. n. med. prof. nadzw. Lucjan Wyrwicz

Speech of congress v-president

prof. dr hab. n. med. Piotr Rutkowski

Speech of congress secretary

dr n. med. Andrzej Kukielka

Speech of ESHO president

prof. EMV&H Gerard van Rhoon

17:35-18:55 **PLENARY SESSION**

17:35-18:15 **Protons and hyperthermia: early clinical results**

Z. Vujaskovic

18:15-18:55 **Building an international forum to boost hyperthermia research**

S. Bodis

19:00-20:30 **COCKTAIL / EXHIBITORS AREA**



Thursday 23rd May 2019

08:30-10:15 **SESSION 1: HYPERTHERMIA QUALITY ASSURANCE**
CHAIRS: S. CURTO, H. DOBSICEK TREFNA

08:15-08:35 **Quality assurance guidelines for hyperthermia**
H. Dobsicek Trefna

08:37- 08:47 **ESHO Quality Assurance guidelines for Interstitial Hyperthermia**
J. Crezee

08:49-08:59 **Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial?**
S. Curto

09:01-09:11 **QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D and 3D techniques.**
G. van Rhoon

09:13-09:23 **Optimized Helmet Applicator Design for Child Brain-Tumor Hyperthermia**
M. Zanoli

09:25-09:35 **Comparison of electro-quasistatic and FDTD calculation methods for modeling of capacitive hyperthermia**
T. Paessler

09:37-09:47 **Inverse source method for element position optimization in modular systems for deep regional hyperthermia**
R. Poni

09:49-09:59 **SAR or temperature-based treatment planning as predictor for temperature changes after phase-amplitude steering during locoregional hyperthermia**
P. Kok

10:01-10:11 **Standardization by a Universal Deep Hyperthermia Treatment Planning System**
T. Drizdal

10:15-10:45 **COFFEE**

10:45-12:15

SESSION 2: HYPERTHERMIA AND IMMUNOTHERAPY

CHAIRS: U. GAIPL, L. LINDNER

10:45-11:05

Immunomodulation by hyperthermia in combination with radiotherapy

U. Gaipf

11:06-11:18

Immunomonitoring of patients with anal carcinoma treated with deep regional hyperthermia in combination with standard radiochemotherapy – first results of the HYCAN trial

A-J. Donaubaue

M. Hader

11:19-11:31

Immune-effects with local hyperthermia

A. Szasz

11:32-11:44

The reduction of the neutrophil / lymphocyte ratio (NLR) is associated with a complete response and disease-free survival in patients with non-invasive bladder cancer treated with intravesical neoadjuvant chemohyperthermia

D. Sousa

11:45-11:57

The effect of hyperthermia on Iscador-treated macrophages

H. M. Kozłowski

11:58-12:10

Can we monitor Immunogenic Cell Death (ICD) induced with modulated electrohyperthermia and oncolytic virus injections ?

S. Van Gool

12:15-13:30

LUNCH

13:30-15:00

SESSION 3: TUMOR BIOLOGY

CHAIRS: U. GAIPL, L. LINDNER

- 13:30-13:50** **Hyperthermia: the optimal treatment to overcome tumor hypoxia**
M. Horsman
- 13:51-14:03** **Differential effects of modulated electro-hyperthermia on slow and fast progressing triple negative breast cancers and the effects of treatment protocol**
P. Hamar
- 14:04-14:16** **Co-evolving model parameter search using cell survival and time-resolved comet data: A holistic view on the synergistic effect of hyperthermia and radiotherapy**
M. Weyland
- 14:17-14:29** **Hyperthermia combined with PARP1-inhibition as radiosensitizer in cervical cancer cells by affecting two DNA DSB repair pathways**
M. IJff
- 14:30-14:42** **Thinking out of the nanoparticle: Externally triggered smart drug delivery systems demand chemotherapeutics with kinetics superior for local delivery**
T. L. M. ten Hagen
- 14:43-14:55** **Does hyperthermia clinically alter the α/β ? Insights from thermoradiotherapy vs. radiotherapy trials**
N. R. Datta

15:00-15:30

COFFEE

15:30-17:00

SESSION 4: CHEMO-RADIOSENSITIZATION

CHAIRS: R. FIETKAU, A. KUKIELKA

15:30-15:50

Combined interstitial radiotherapy with interstitial hyperthermia

A. Kukielka

15:51-16:03

Molecular basis of modulated electro-hyperthermia combination with radio- and chemo-therapies

O. Szasz

16:04-16:16

Improving Hyperthermia-Based Anti-Cancer Treatments by Modulation of the Heat Shock Response

E. Scutigliani

16:17-16:29

Elevated apoptosis and tumor stem cell destruction in a radioresistant pancreatic adenocarcinoma cell line when radiotherapy is combined with modulated electro-hyperthermia

G. Fórika

16:30-16:42

Institutional variations in Hyperthermic Intraperitoneal Chemotherapy

R. Helderman

16:43-16:55

Can the combination of hyperthermia with low LET radiation have an equivalent anti-tumor effect as seen with high LET radiation alone?

P. Elming

17:00-18:30

AWARD SESSION

Int. J. Hyperthermia Awards by G.C. van Rhoon
ESHO young investigator Awards by G.C. van Rhoon
ESHO/Pyrexar Awards introduction by J. Crezee
ESHO/Pyrexar Awards winner presentation

20:00

GALA DINNER

Friday

24th May 2019

08:45-10:40 **SESSION 5: ONGOING CLINICAL STUDIES**
CHAIRS: R. WESSALOWSKI, L. WYRWICZ

8:45-9:05 **Hyperthermia in Poland**
L. Wyrwicz

9:06-9:18 **Focused ultrasound-induced hyperthermia as radiosensitizer for glioblastoma, prostate cancer and head and neck cancer cell lines**
X. Zhang

9:19-9:31 **Radiotherapy combined with Hyperthermia in the treatment of recurrent cancer of the head and neck region. Impact in early response and quality of life**
M. A. Costa

9:32-9:44 **Correlation between thermal dose and tumor control/ hyperthermia associated toxicity in recurrent breast cancer treated with thermoradiation**
A. Bakker, J. Crezee

9:45-9:57 **Feasibility study of the hyperthermia treatment planning software Hyperplan™ on the new BSD-2000 3D / MRI in a patient with high-risk soft tissue sarcoma of the lower extremity**
B. Zilles

9:58-10:10 **Evolution of Local-Regional and Whole-Body Hyperthermia in Portugal**
J. Moreira-Pinto

10:11-10:23 **The level of evidence for the medical indications of Whole-body hyperthermia (WBH) - Guideline for mild and fever-range WBH**
Hüseyin Sahinbas

10:24-10:36 **Susceptibility to hyperthermia treatment through CTCs study**
P. Apostolou

10:40-11:00 **COFFEE**

11:00-12:30

SESSION 6: FLASH POSTER PRESENTATIONS

CHAIRS: A. BAKKER, P. WUST

12:30-13:45

LUNCH

13:45-15:25

SESSION 7: RECENT CLINICAL TRIALS

CHAIRS: M. FRANCKENA, P. RUTKOWSKI

13:30-13:50

Erlangen University: Results of RT+HT clinical trials

R. Fietkau

13:51-14:03

Proton therapy and hyperthermia in bulky, treatment-resistant extra-abdominal desmoid tumours

E. Stutz

14:04-14:16

Combined wIRA-hyperthermia and repeat re-irradiation (re-re-RT) in the management of re-recurrences of locally recurrent breast cancer

M. Notter

14:17-14:29

Effects of modulated electro-hyperthermia on disease control and 3 year disease-free survival in locally advanced cervical cancer patients: Preliminary results

C. Minnaar

14:30-13:42

Hyperthermia and radiation for locally advanced cervical carcinoma: temperature matters

M. Franckena

14:43-14:55

Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study

N. R. Datta

14:56-15:08

Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer

R. Wessalowski

15:09-15:29

New clinical strategies

S. Bodis

15:25-16:00

COFFEE

16:00-17:45

SESSION 8: MR-BASED HYPERTHERMIA

CHAIRS: N.R. DATTA, T. NIENDORF

16:00-16:20

Progress of MR-guided thermal intervention for brain tumors

T. Niendorf

16:21-16:33

Potential impact of MR-only treatment planning for MR guided deep pelvic hyperthermia

I. V. Boas-Ribeiro

16:34-16:46

Thermal Therapy of the Porcine Pancreas in-vivo using MR-Guided HIFU

L. Sebeke

16:47-16:59

Design and validation of the MRcollar: the first clinical grade MR-guided head and neck applicator

G. G. Bellizzi

17:00-17:12

MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms

P.F. Turner

17:13-17:25

Physical rationale and empirical data about mEHT as a low resource setting to treat brain tumors

P. Wust

17:26-17:38

Hyperthermia and radiation induced MR diffusion changes in brain glioma tumour treatment

L. Khalafi

17:30-18:00

CLOSING CEREMONY